ENGNW — enGene Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1980845 ·
Quebec, Canada
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -31,968,000 | -30,227,000 | 307,524,000 | 29,827,000 | 52,356,000 |
| Jan 2026 | 0 | — | -31,185,000 | -29,752,000 | 337,113,000 | 36,613,000 | 55,567,000 |
| Oct 2025 | 0 | — | -39,481,000 | -37,880,000 | 221,468,000 | 50,152,000 | 53,758,000 |
| Jul 2025 | 0 | — | -29,947,000 | -28,991,000 | 245,550,000 | 32,623,000 | 44,878,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,997,000
Investing CF
$-60,780,000
Financing CF
$143,058,000
CapEx
$-1,392,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-21
Balance + Analyst (yfinance extras)
Retained Earnings
$-432,011,000
Inventory
—
Receivables
$822,000
ST Investments
$228,638,000
EBIT TTM
$-124,123,000
Pretax Income TTM
$-127,108,000
Interest Exp TTM
$2,985,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -123,165,000 | -117,302,000 | 221,468,000 | 53,758,000 | — | -99,239,000 |
| Oct 2024 | 0 | -62,297,000 | -55,142,000 | 311,173,000 | 38,561,000 | — | -48,281,000 |
| Oct 2023 | 0 | -26,060,000 | -99,917,000 | 86,959,000 | 14,473,000 | — | -24,743,000 |
| Oct 2022 | 0 | -19,427,000 | -24,462,000 | 23,909,000 | 47,405,000 | — | -17,592,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $239.95B | $443.84 | — |
| GILD | GILEAD SCIENCES, INC. | $181.95B | $146.74 | — |
| ARGX | ARGENX SE | $63.26B | $1011.11 | — |
| MRNA | Moderna, Inc. | $55.45B | $138.89 | — |
| RVMD | Revolution Medicines, Inc. | $45.35B | $211.58 | — |
News headlines (Yahoo Finance, 1h cache)
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
2026-07-16 12:00 · Yahoo
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
2026-08-13 15:07 · Yahoo
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
2026-08-04 12:00 · Yahoo
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
2026-07-15 13:00 · Yahoo
Neumora depression drug fails; EnGene to cut 50% of staff
2026-06-16 09:08 · Yahoo
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-06-15 13:00 · Yahoo
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations
2026-05-11 01:11 · Yahoo
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
2026-05-08 23:05 · Yahoo
enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?
2026-05-08 21:27 · Yahoo
enGene Therapeutics hit by analyst downgrades as drug data disappoints
2026-05-08 15:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.